AstraZeneca, Daiichi Sankyo score tenth BTD for Enhertu in early HER2 disease

AstraZeneca PLC (LON: AZN) and Daiichi Sankyo have secured a Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration for Enhertu (trastuzumab deruxtecan) as post-neoadjuvant therapy in HER2-positive early breast cancer patients with residual invasive disease. The designation follows positive data from the DESTINY-Breast05 Phase III trial and marks the tenth BTD for Enhertu across oncology indications.

The move expands AstraZeneca and Daiichi Sankyo’s regulatory lead in HER2-directed antibody-drug conjugates (ADCs) and sets the stage for Enhertu to challenge trastuzumab emtansine (T-DM1) as the standard of care in a high-risk, pre-metastatic population.

Why is post-neoadjuvant HER2-positive early breast cancer such a high-stakes battleground in 2025?

The designation targets patients with HER2-positive early breast cancer who, despite neoadjuvant therapy, retain invasive disease in breast or axillary nodes—a group known to carry a high risk of recurrence and progression to metastatic cancer. Roughly half of such patients fail to achieve a pathologic complete response (pCR) following neoadjuvant treatment, and current post-neoadjuvant options like T-DM1 still leave around 20 percent exposed to recurrence or death, with limited protection against central nervous system metastasis.

The FDA’s decision to grant BTD to Enhertu is grounded in DESTINY-Breast05, which directly compared Enhertu to T-DM1 in this setting. Presented at the 2025 European Society for Medical Oncology Congress and published in The New England Journal of Medicine, the trial showed a clinically meaningful benefit in invasive disease-free survival (IDFS) for Enhertu, though full data on overall survival and brain metastasis-free intervals are still maturing.

For regulators and oncologists alike, Enhertu’s apparent superiority in preventing recurrence is particularly significant given the steep drop in survival once metastatic disease takes hold. Five-year survival plunges from nearly 90% in localized HER2-positive cases to approximately 30% after metastasis.

How does DESTINY-Breast05 reposition Enhertu as a first-choice ADC in early-stage HER2 cancer?

DESTINY-Breast05 represents a strategic shift for Enhertu—from a drug best known for metastatic settings into earlier lines of intervention. While Enhertu already dominates second-line metastatic HER2-positive breast cancer following the DESTINY-Breast03 trial, and has made gains in HER2-low and HER2-ultralow indications, this marks one of its first major head-to-head showdowns in the curative-intent early disease window.

Crucially, DESTINY-Breast05 enrolled over 1,600 patients worldwide with residual invasive disease post-neoadjuvant therapy and randomized them to Enhertu or T-DM1. The trial’s primary endpoint, investigator-assessed IDFS, is a stringent marker particularly suited to high-risk recurrence populations.

While detailed subgroup data is still pending, the headline result is clear: Enhertu outperformed the incumbent therapy and reinforced its profile as the HER2-directed ADC with the broadest and most consistent clinical validation across early and late-stage disease.

What strategic advantages does the BTD confer on AstraZeneca and Daiichi Sankyo?

The Breakthrough Therapy Designation accelerates review timelines and opens the door to more frequent regulatory engagement and rolling submissions. For AstraZeneca and Daiichi Sankyo, this fast-tracked review positions Enhertu for a potential approval in the post-neoadjuvant setting well ahead of competitors and grants a valuable marketing advantage.

The BTD also strengthens Enhertu’s moat as the lead ADC asset in breast oncology. The drug is already approved in more than 90 countries for HER2-positive metastatic breast cancer, and in over 85 jurisdictions for HER2-low indications. With ongoing filings in HER2-ultralow and tumor-agnostic settings, Enhertu has become the lynchpin of both companies’ oncology growth strategies.

From a regulatory standpoint, Enhertu’s rapid expansion into earlier treatment windows reflects growing FDA comfort with ADCs as first-line and even preemptive treatments, particularly in indications with strong biomarker stratification and historical unmet need.

How does Enhertu compare to other ADC strategies and what risks remain?

While Enhertu’s clinical efficacy is now well documented, its safety profile continues to warrant attention, particularly regarding interstitial lung disease (ILD), which has emerged as a class effect concern for topoisomerase I inhibitor-based ADCs. Managing ILD risk in patients with curative intent could pose tighter tolerability constraints than in metastatic settings.

Moreover, the durability of Enhertu’s benefit compared to T-DM1 over longer timelines—including CNS recurrence and overall survival endpoints—will be closely watched. Despite the positive IDFS data, some experts remain cautious about extrapolating those findings to real-world populations with co-morbidities or limited access to early diagnosis and standard neoadjuvant care.

Competitively, companies such as Seagen (now Pfizer), ImmunoGen, and Mersana are pushing next-generation HER2 or TROP2-targeting ADCs with different linker-payload architectures, some of which aim to improve safety while preserving efficacy. Still, none have matched Enhertu’s clinical breadth or secured as many regulatory wins across tumor types.

What are the commercial and pipeline implications for AstraZeneca and Daiichi Sankyo?

The post-neoadjuvant approval would extend Enhertu’s commercial reach into a new segment of early breast cancer patients who have not yet progressed to advanced disease. This could significantly expand the addressable market while also embedding the drug earlier in the treatment paradigm, potentially influencing downstream treatment sequencing and positioning Enhertu as a foundational ADC.

For Daiichi Sankyo, the pipeline impact is equally critical. Enhertu is the company’s lead asset, and its ongoing collaboration with AstraZeneca (extended in March 2024 and worth up to $6 billion) funds not only Enhertu development but also Datroway (datopotamab deruxtecan) and other DXd-based ADCs in breast, lung, and gastrointestinal cancers.

If the FDA converts the BTD into an approval by mid-2026, Enhertu could become the first HER2-directed ADC to secure a clean regulatory sweep across metastatic, HER2-low, and early breast cancer stages—an outcome that would redefine HER2 treatment pathways globally.

Key takeaways: What this FDA designation means for Enhertu and the ADC oncology landscape

• Enhertu has received its tenth Breakthrough Therapy Designation, this time for post-neoadjuvant HER2-positive early breast cancer with residual disease.
• DESTINY-Breast05 demonstrated a statistically significant IDFS benefit over T-DM1, potentially setting a new standard of care for this high-risk group.
• The BTD accelerates Enhertu’s path to market in a new segment, giving AstraZeneca and Daiichi Sankyo a strategic edge in early disease settings.
• Enhertu’s broad efficacy across HER2-positive, HER2-low, and HER2-ultralow populations makes it the most versatile ADC in current clinical use.
• Safety concerns, particularly ILD, remain relevant as the drug moves into curative-intent populations with tighter risk tolerance.
• Competitive ADC pipelines are expanding, but no rival has yet matched Enhertu’s regulatory momentum or clinical validation breadth.
• Approval in this setting could significantly expand Enhertu’s commercial opportunity while reshaping HER2 treatment paradigms from early to metastatic disease.
• The designation further solidifies Daiichi Sankyo’s ADC platform leadership and deepens AstraZeneca’s commitment to redefining breast cancer care.